Search

Your search keyword '"Vitello, G."' showing total 3 results
Start Over Author "Vitello, G." Journal neurological sciences
3 results on '"Vitello, G."'

2. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.

Author

Sangalli, F., Moiola, L., Bucello, S., Annovazzi, P., Rizzo, A., Radaelli, M., Vitello, G., Grimaldi, L., Ghezzi, A., Martinelli, V., and Comi, G.

Subjects
MONOCLONAL antibodies, DRUG efficacy, DRUG tolerance, MULTIPLE sclerosis treatment, DISEASE relapse, MAGNETIC resonance imaging, MEDICAL imaging systems
Abstract

To evaluate the efficacy and safety of natalizumab in patients with active relapsing-remitting multiple sclerosis (MS). We included 285 MS patients receiving natalizumab. Clinical, neuroradiological and safety data were registered every 6 months. Neutralizing antibodies (NABs) were tested after 6 months of treatment. After 1 year, the annualized relapse rate decreased to 0.26, with a significant reduction compared to the previous year (2.13). At 24 months the proportion of 'relapse free' patients was 78% while that of 'MRI free' patients was 69%. Considering clinical and MRI cumulative activity, 'disease free' patients were 63% at 24 months. A total of 18 patients showed NABs positivity. We reported 34 cases of treatment interruptions. In conclusion, our data confirm the remarkable efficacy of natalizumab in a group of patients with higher disease activity than that of pivotal studies. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

3. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

Author

Annalisa Rizzo, L.M.E. Grimaldi, G. Vitello, Pietro Annovazzi, A. Ghezzi, Vittorio Martinelli, Marta Radaelli, Francesca Sangalli, S. Bucello, Lucia Moiola, G. Comi, Sangalli, F, Moiola, L, Bucello, S, Annovazzi, P, Rizzo, A, Radaelli, M, Vitello, G, Grimaldi, Lm, Ghezzi, A, Martinelli, V, and Comi, Giancarlo

Subjects
Adult, Male, medicine.medical_specialty, Neurology, Efficacy, Dermatology, Antibodies, Monoclonal, Humanized, Follow-Up Studie, Cohort Studies, Drug Hypersensitivity, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Internal medicine, Product Surveillance, Postmarketing, medicine, Humans, Multiple sclerosi, Young adult, business.industry, Multiple sclerosis, General Medicine, Middle Aged, medicine.disease, Surgery, Psychiatry and Mental health, Treatment Outcome, Tolerability, Psychiatry and Mental Health, Female, Observational study, Neurology (clinical), Neurosurgery, Safety, Cohort Studie, business, Human, Follow-Up Studies, Cohort study, medicine.drug
Abstract

To evaluate the efficacy and safety of natalizumab in patients with active relapsing-remitting multiple sclerosis (MS). We included 285 MS patients receiving natalizumab. Clinical, neuroradiological and safety data were registered every 6 months. Neutralizing antibodies (NABs) were tested after 6 months of treatment. After 1 year, the annualized relapse rate decreased to 0.26, with a significant reduction compared to the previous year (2.13). At 24 months the proportion of "relapse free" patients was 78% while that of "MRI free" patients was 69%. Considering clinical and MRI cumulative activity, "disease free" patients were 63% at 24 months. A total of 18 patients showed NABs positivity. We reported 34 cases of treatment interruptions. In conclusion, our data confirm the remarkable efficacy of natalizumab in a group of patients with higher disease activity than that of pivotal studies. © Springer-Verlag 2010.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results